awmsg logo



rifaximin (Xifaxanta®)


Reference No. 1232

Publication date:
27/07/2012


Last review date:
30/08/2016

Appraisal information

rifaximin (Xifaxanta®) 200 mg film-coated tablet


Company: Norgine Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 15/05/2012
AWMSG meeting date: 20/06/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1212
Ministerial ratification: 23/07/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Rifaximin (Xifaxanta®) is recommended as an option for use within NHS Wales for the treatment of travellers’ diarrhoea that is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes in the stool or to shorten the duration of diarrhoea when this is associated with non-invasive strains of E.coli.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download